Cassava Sciences Inc. traded at $26.51 this Friday July 1st, decreasing $1.61 or 5.73 percent since the previous trading session. Looking back, over the last four weeks, Cassava Sciences Inc. lost 3.81 percent. Over the last 12 months, its price fell by 70.56 percent. Looking ahead, we forecast Cassava Sciences Inc. to be priced at 25.79 by the end of this quarter and at 23.75 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
26.51
Daily Change
-5.73%
Yearly
-70.56%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Eisai 5,825.00 134.00 2.35% -44.52%
Abbott 110.22 1.57 1.45% -6.62%
AcelRx Pharmaceuticals 0.26 0.01 5.61% -80.75%
Acura Pharmaceuticals 0.50 0.02 3.96% -19.84%
Amgen 245.55 2.25 0.92% -1.27%
Biogen 210.63 6.69 3.28% -39.60%
Cara Therapeutics 8.62 -0.51 -5.59% -40.06%
Geron 1.67 0.12 7.74% 14.38%
J&J 179.52 2.01 1.13% 6.24%
Eli Lilly 324.71 0.48 0.15% 38.79%
Merck & Co 92.42 1.25 1.37% 17.58%
Novartis 81.65 1.32 1.64% -3.02%
Novavax 57.15 5.72 11.12% -73.69%
Pfizer 52.31 -0.12 -0.23% 31.66%
Cassava Sciences Inc. 26.51 -1.61 -5.73% -70.56%
Roche Holding 322.10 1.70 0.53% -8.06%

Indexes Price Day Year
USND 11128 99.11 0.90% -23.99%
US2000 1728 19.77 1.16% -25.07%

Cassava Sciences Inc.
Cassava Sciences, Inc. is a clinical-stage biotechnology company. The Company is focused on developing the drug for the treatment of neurodegenerative diseases, such as Alzheimers disease. The Company’s products include Simufilam and SavaDx. Its lead therapeutic product candidate, Simufilam, is a proprietary small molecule (oral) drug. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimers brain. The SavaDx, is an early-stage program focused on detecting the presence of Alzheimers disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is also developing SavaDx is a quantitative blood-based investigational biomarker/diagnostic to detect and monitor Alzheimer's disease. The Company’s scientific approach for the treatment of Alzheimers disease seeks to simultaneously progress both neurodegeneration and neuroinflammation.